Zolbetuximab - Difference Between Vyloy and Rituximab

Zolbetuximab (Zolbetuximab)-Vyloy and rituximab (Rituximab) are both monoclonal antibody drugs, but they have significant differences in their mechanisms of action, indications and clinical applications. Zotuximab is an innovative drug targeting CLDN18.2. It is mainly used to treat CLDN18.2-positive advanced or metastatic gastric cancer and gastroesophageal junction adenocarcinoma. Its mechanism of action is through precise recognition and binding of CLDN18.2 protein, inhibiting the growth of tumor cells and activating the immune system to kill tumors. This targeted treatment strategy provides new hope for gastric cancer patients, especially in patients with high expression of CLDN18.2, zotuximab combined with chemotherapy has shown significant efficacy.

In contrast, rituximab is a monoclonal antibody that targetsCD20 and is mainly used to treat B-cell malignancies such as non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Rituximab binds to the CD20 antigen on the surface of B cells, inducing apoptosis or clearing tumor cells through immune mechanisms. Since its approval in 1997, rituximab has become one of the cornerstone drugs in the treatment of hematological tumors, significantly improving patients' survival and quality of life.

From the perspective of indications, zotuximab and rituximab target solid tumors and hematological tumors respectively, reflecting the wide application of monoclonal antibody drugs in different tumor types. In addition, the side effect profiles of the two are also different. Common adverse reactions of zotuximab include nausea, vomiting and infusion-related reactions, while rituximab may cause immune-related side effects such as infection and cytopenia. Therefore, when using these drugs, doctors will develop individualized treatment plans based on the patient's specific conditions and closely monitor adverse reactions.

Reference materials:https://www.sciencedirect.com/science/article/pii/S1347861324000343